<?xml version='1.0' encoding='utf-8'?>
<document id="30605260"><sentence text="No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects."><entity charOffset="13-23" id="DDI-PubMed.30605260.s1.e0" text="Plazomicin" /><entity charOffset="51-60" id="DDI-PubMed.30605260.s1.e1" text="Metformin" /><pair ddi="false" e1="DDI-PubMed.30605260.s1.e0" e2="DDI-PubMed.30605260.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30605260.s1.e0" e2="DDI-PubMed.30605260.s1.e1" /></sentence><sentence text="Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside-modifying enzymes, which are the most common aminoglycoside resistance mechanism in Enterobacteriaceae"><entity charOffset="0-10" id="DDI-PubMed.30605260.s2.e0" text="Plazomicin" /><entity charOffset="17-31" id="DDI-PubMed.30605260.s2.e1" text="aminoglycoside" /><entity charOffset="64-78" id="DDI-PubMed.30605260.s2.e2" text="aminoglycoside" /><entity charOffset="124-138" id="DDI-PubMed.30605260.s2.e3" text="aminoglycoside" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e0" e2="DDI-PubMed.30605260.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e0" e2="DDI-PubMed.30605260.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e0" e2="DDI-PubMed.30605260.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e0" e2="DDI-PubMed.30605260.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e1" e2="DDI-PubMed.30605260.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e1" e2="DDI-PubMed.30605260.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e1" e2="DDI-PubMed.30605260.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e2" e2="DDI-PubMed.30605260.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30605260.s2.e2" e2="DDI-PubMed.30605260.s2.e3" /></sentence><sentence text=" Because plazomicin is predominantly eliminated via renal pathways, an in vitro study was conducted to determine whether plazomicin inhibits the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion (MATE1 and MATE2-K) transporters, using metformin as a probe substrate"><entity charOffset="9-19" id="DDI-PubMed.30605260.s3.e0" text="plazomicin" /><entity charOffset="121-131" id="DDI-PubMed.30605260.s3.e1" text="plazomicin" /><entity charOffset="259-268" id="DDI-PubMed.30605260.s3.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30605260.s3.e0" e2="DDI-PubMed.30605260.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30605260.s3.e0" e2="DDI-PubMed.30605260.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30605260.s3.e0" e2="DDI-PubMed.30605260.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30605260.s3.e1" e2="DDI-PubMed.30605260.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30605260.s3.e1" e2="DDI-PubMed.30605260.s3.e2" /></sentence><sentence text=" Plazomicin inhibited OCT2, MATE1, and MATE2-K transporters with half-maximal inhibition of the transporter values of 5120, 1300, and 338 µg/mL, respectively"><entity charOffset="1-11" id="DDI-PubMed.30605260.s4.e0" text="Plazomicin" /></sentence><sentence text=" To determine whether this in vitro inhibition translates in vivo, an open-label, randomized, 2-period, 2-treatment crossover study (NCT03270553) was carried out in healthy subjects (N = 16), who received a single oral dose of metformin 850 mg alone and in combination with a single intravenous infusion of plazomicin 15 mg/kg"><entity charOffset="227-236" id="DDI-PubMed.30605260.s5.e0" text="metformin" /><entity charOffset="307-317" id="DDI-PubMed.30605260.s5.e1" text="plazomicin" /><pair ddi="false" e1="DDI-PubMed.30605260.s5.e0" e2="DDI-PubMed.30605260.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30605260.s5.e0" e2="DDI-PubMed.30605260.s5.e1" /></sentence><sentence text=" Geometric least-squares mean ratios of the test treatment (combination) vs the reference treatment (metformin alone) and 90% confidence intervals were within the equivalence interval of 80% to 125% (peak plasma concentration, 104"><entity charOffset="101-110" id="DDI-PubMed.30605260.s6.e0" text="metformin" /></sentence><sentence text="5 [95" /><sentence text="1-114" /><sentence text="9]; area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, 103" /><sentence text="7 [93" /><sentence text="5-115" /><sentence text="0]; area under the plasma concentration-time curve from time zero to infinity, 104" /><sentence text="0 [94" /><sentence text="2-114" /><sentence text="8])" /><sentence text=" The results demonstrate that there is no clinically significant drug-drug interaction resulting from coadministration of single doses of intravenous plazomicin 15 mg/kg and oral metformin 850 mg in healthy subjects"><entity charOffset="150-160" id="DDI-PubMed.30605260.s16.e0" text="plazomicin" /><entity charOffset="179-188" id="DDI-PubMed.30605260.s16.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30605260.s16.e0" e2="DDI-PubMed.30605260.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30605260.s16.e0" e2="DDI-PubMed.30605260.s16.e1" /></sentence><sentence text=" Coadministration of plazomicin and metformin was well tolerated in healthy subjects"><entity charOffset="21-31" id="DDI-PubMed.30605260.s17.e0" text="plazomicin" /><entity charOffset="36-45" id="DDI-PubMed.30605260.s17.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30605260.s17.e0" e2="DDI-PubMed.30605260.s17.e0" /><pair ddi="false" e1="DDI-PubMed.30605260.s17.e0" e2="DDI-PubMed.30605260.s17.e1" /></sentence><sentence text="" /></document>